Parent hub for Retatrutide vial strengths: 10 mg, 20 mg, 30 mg and 40 mg lyophilised research peptide. Compare presentations, working concentrations and reconstitution volumes at a glance.
BuyRetaUK supplies Retatrutide (LY3437943) in four lyophilised vial strengths: 10 mg, 20 mg, 30 mg and 40 mg. Each strength is manufactured under a single release framework, tested by reversed-phase HPLC-UV for purity and ESI-MS for identity, and released against the same ≥99% area-percent specification. The strength on the vial defines the total peptide mass; the working concentration is set at the bench by choosing an appropriate reconstitution volume.
Every batch resolves to a batch-specific Certificate of Analysis in the public verification library, indexed by the batch number printed on the vial label. Strength selection is therefore independent of quality — quality is invariant across the four strengths — and is driven by laboratory planning considerations covered below.
Every vial ships with a batch-specific COA · UK dispatch
Strength selection is a planning decision, not a dosage recommendation. The relevant inputs are the total peptide mass a protocol requires, the reconstitution volume the laboratory prefers to standardise on, and the working concentration needed at the bench. Because working concentration is a function of vial strength divided by reconstitution volume, several combinations can produce the same result — the reconstitution calculator translates strength and volume into concentration for any target workflow.
Handling of reconstituted material — refrigeration windows, freeze-thaw limits and light exposure — is covered in the Retatrutide storage guide.
| Strength | Price | Profile | Laboratory note |
|---|---|---|---|
| 10 mg | £59 | Entry-strength vial for short workflows or method-development runs where a small total mass is preferred. | Smaller reconstitution volumes deliver higher working concentrations from a single vial. |
| 20 mg | £90 | Mid-range vial suited to routine multi-well or multi-plate laboratory experimentation. | Balances working-solution longevity with reduced freeze-thaw exposure per vial. |
| 30 mg | £110 | Extended-run vial for longer studies or larger reconstitution volumes. | Well-suited to laboratories standardising on a single reconstitution volume across multiple experiments. |
| 40 mg | £145 | Highest available strength for sustained workflows and larger-scale in-vitro programmes. | Consolidates a research programme onto fewer batches, simplifying batch-to-batch reconciliation. |
All strengths share the same ≥99% HPLC-UV release specification and batch-specific Certificate of Analysis. Prices are per vial and subject to change; confirm on the product page.
| Research scenario | Recommended | Rationale |
|---|---|---|
| Entry-strength vial for short workflows or method-development runs where a small total mass is preferred. | Retatrutide 10 mg — £59 | Smaller reconstitution volumes deliver higher working concentrations from a single vial. |
| Mid-range vial suited to routine multi-well or multi-plate laboratory experimentation. | Retatrutide 20 mg — £90 | Balances working-solution longevity with reduced freeze-thaw exposure per vial. |
| Extended-run vial for longer studies or larger reconstitution volumes. | Retatrutide 30 mg — £110 | Well-suited to laboratories standardising on a single reconstitution volume across multiple experiments. |
| Highest available strength for sustained workflows and larger-scale in-vitro programmes. | Retatrutide 40 mg — £145 | Consolidates a research programme onto fewer batches, simplifying batch-to-batch reconciliation. |
Regardless of strength, every BuyRetaUK Retatrutide vial is manufactured to the same synthesis and release framework. Release testing combines reversed-phase HPLC-UV for purity, ESI-MS for identity, and — where relevant — Karl Fischer moisture determination and endotoxin testing. The methodology and acceptance criteria are documented on the laboratory quality page.
Reverse-phase HPLC quantifies purity as a percentage of total peak area. Release specification: ≥99%.
Learn more →Certificate of AnalysisEvery batch ships with a batch-specific COA reporting identity, purity and appearance.
Learn more →Laboratory QualityIndependent third-party analysis, temperature-controlled UK storage and full batch traceability.
Learn more →Batch VerificationCross-reference the batch number printed on your vial against our live COA library.
Learn more →Storage StandardsLyophilised at 2–8°C protected from light. Reconstituted stability ~30 days at 2–8°C.
Learn more →Every vial — 10 mg through 40 mg — is released with a batch-specific Certificate of Analysis that reports identity, HPLC-UV purity, appearance and, where determined, moisture and endotoxin. Batch numbers on the vial label resolve to their COA in the public verification library. The anatomy of a COA — section by section — is covered in the Certificate of Analysis guide.
Purity is the analytically determined fraction of the target peptide in a batch, measured by reversed-phase HPLC with UV detection at 214 nm and expressed as area-percent. BuyRetaUK Retatrutide is released at ≥99% area-percent HPLC-UV, with identity confirmed independently by mass spectrometry. Method deep-dive, chromatography parameters and interpretation guidance are covered on the Retatrutide purity page.
Storage requirements do not vary by vial strength. Lyophilised Retatrutide is stable at 2–8 °C in the short term and at −20 °C for longer-term retention; reconstituted working solution is refrigerated and consumed within a limited window with minimised freeze-thaw exposure. Full cold-chain handling and freeze-thaw guidance is documented in the Retatrutide storage guide.
Choose the vial mass that covers your total workflow with the fewest batch changes.
Fix a reconstitution volume across a study so working concentration scales predictably with strength.
Regardless of strength, resolve the vial's batch number in the verification library before use.
Aliquot reconstituted material to minimise freeze-thaw cycles — larger vials benefit most from disciplined aliquoting.
BuyRetaUK supplies Retatrutide in four lyophilised vial strengths: 10 mg, 20 mg, 30 mg and 40 mg. All four share the same ≥99% HPLC-UV release specification and mass-spectrometric identity confirmation, and each ships with a batch-specific Certificate of Analysis.
No. Every Retatrutide strength is released against the same analytical specification. The vial label carries the batch number; the batch COA in the verification library documents the release purity and identity result.
Strength selection is a laboratory-planning decision. Consider the total mass your protocol requires, the reconstitution volume you plan to use, the working concentration you need at the bench, and how quickly the reconstituted material will be consumed. The reconstitution calculator translates vial strength and volume into a concentration.
Not by itself. Working concentration is set by the ratio of vial strength to reconstitution volume. A 40 mg vial reconstituted in 4 mL produces the same concentration as a 10 mg vial reconstituted in 1 mL.
BuyRetaUK does not stock a dedicated 5 mg vial. Researchers requiring a 5 mg equivalent typically use a 10 mg vial and adjust the reconstitution volume accordingly. Details are in the Retatrutide 5 mg planning reference.
Yes. Every BuyRetaUK Retatrutide vial — regardless of strength — is produced under the same synthesis and release framework, with orthogonal HPLC-UV purity and mass-spectrometric identity testing.
Every vial carries a batch identifier that resolves to its Certificate of Analysis in the public verification library. Read the batch number, open the COA, and confirm the analytical release data before use.
No. Storage is governed by the physical form (lyophilised vs reconstituted) and environment, not by vial mass. The Retatrutide storage guide covers cold-chain handling and freeze-thaw considerations for all strengths.
Peer-reviewed citations are added as each article is expanded. See our editorial standards for our sourcing and accuracy commitments.
The BuyRetaUK editorial team publishes laboratory-focused reference content on research peptides, analytical methods and Certificates of Analysis. All articles are written for in-vitro research contexts only.
View profile →Every editorial article is reviewed against our accuracy commitment and quality-assurance checklist before publication. Named reviewer profiles are added as our reviewer network expands.
View profile →Every article follows a documented editorial process — sourcing, scientific review, update cadence and correction policy — so researchers can rely on what we publish.
Read the full editorial standards →Educational first. Each step is optional — start wherever you are in your research.
Compound overview, receptor profile and research framing.
Triple vs dual incretin agonist — how they differ.
Triple agonist vs single GLP-1 agonist.
How to verify identity, purity and batch quality.
Every retatrutide variant with lab data.
Solvent volume and dose-per-unit calculator.
Triple vs dual incretin agonist — receptor profile and research framing.
View comparison →Side by sideTriple agonist vs single GLP-1 — class, mechanism and lab context.
View comparison →Multi-compoundAll GLP-1 / GIP / glucagon research compounds in one place.
View comparison →Every batch of Retatrutide ships with a third-party HPLC and mass-spec Certificate of Analysis. Browse the live COA library to verify your lot.
The UK laboratory reference for research-grade Retatrutide.
Read reference →HandlingRetatrutide StorageCold-chain, freeze-thaw and reconstitution guidance for every strength.
Open storage guide →AnalyticalRetatrutide PurityHPLC-UV testing, batch verification and COA interpretation.
Open purity guide →
